MoonLake Immunotherapeutics has seen sharp swings over the past few years, and the latest share price level puts fresh focus on a simple question for you as an investor: Is the current valuation of MoonLake Immunotherapeutics stock meaningfully backed up by the strength of its balance sheet and its book value per share? Over the last 3 years the share price has fallen 66.5%, which puts a lot of weight on whether the current market value still lines up with the underlying net assets on the...
MoonLake Immunotherapeutics (MLTX) just posted third quarter 2026 results, reporting a net loss of US$79.55 million and a diluted loss per share of US$0.93. The company also reaffirmed its focus on sonelokimab regulatory milestones. The latest earnings update landed after a sharp pullback, with MoonLake Immunotherapeutics now trading at US$12.56. The 7 day share price return of 7.35% and 30 day gain of 16.08% suggest short term momentum is rebuilding, even though the 90 day share price return...
MoonLake Immunotherapeutics BLA filing for sonelokimab in HS, VELA phase 3 HiSCR75 data, and PsA IZAR-1 readouts—click to see what’s next for MLTX investors.
MoonLake Immunotherapeutics (MLTX) could receive US Food and Drug Administration approval for sonelo
Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.
ZUG, Switzerland, August 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive...
This is the newest page. Registered accounts read further back.